In a trial featuring a mouse model of Alzheimer's, scientists found that inhaling a mixture containing xenon gas helped ...

Scientists have come up with a drug that is a potential candidate for tackling memory deficits in the early stages of the disease in rodents. Research shows that the drug activates the cannabinoid ...

Cognitive profiles for early diagnosis of Dementia with Lewy bodies (DLB) have been outlined in a new study. Although DLB is the second most common neurodegenerative dementia following Alzheimer's ...

Most treatments being pursued today to protect against Alzheimer's disease focus on amyloid plaques and tau tangles that ...

The FDA has accepted the BLA for lecanemab-irmb SC for weekly maintenance dosing in the treatment of early Alzheimer disease.

Anavex Life Sciences shares were up 7% to $11.25 after the company said it saw positive trial results for its oral blarcamesine for the treatment of early Alzheimer's disease. The clinical-stage ...

A breakthrough study highlights Xenon gas as a potential game-changer in treating Alzheimer’s disease, demonstrating its ...

Dartmouth Health is the only health care system on the East Coast to be part of the newly launched Brain Health Navigator ...

Activation of SIGMAR1 is expected to restore cellular homeostasis by inducing autophagy, which may slow neurodegeneration in patients with early AD.

Blarcamesine potential novel oral treatment to target upstream Alzheimer’s disease pathology through autophagy enhancement Impairment of autophagy precedes both amyloid beta and tau tangles, and ...

A Prescription Drug User Fee Act target date of August 31, 2025 has been set for the application. The Food and Drug Administration (FDA) has accepted the Biologics License Application (BLA) for ...

Quality time takes on a whole new meaning after an Alzheimer’s diagnosis. “We just finished a two-week European River cruise, ...